Skip to Main Content
American Society of Hematology Logo Open Menu
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 2013, Issue 1
December 6 2013
Hematology Cover Image for Volume 2013, Issue 1
In this Issue

Table of Contents

Ham-Wasserman Manuscript

Iron and hepcidin: a story of recycling and balance
Clara Camaschella
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Choosing Wisely®

The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question
Lisa K. Hicks,Harriet Bering,Kenneth R. Carson,Judith Kleinerman,Vishal Kukreti,Alice Ma,Brigitta U. Mueller,Sarah H. O'Brien,Marcelo Pasquini,Ravindra Sarode,Lawrence Solberg, Jr,Adam E. Haynes,Mark A. Crowther
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

A Fresh Look at Drug Approval: Moving Away from Tradition

Phase 4 research: what happens when the rubber meets the road?
Mark Crowther
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Drug discovery in rare indications: opportunities and challenges
Victoria M. Richon
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Accelerating safe drug development: an ideal approach to approval
Michael R. Grever
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Advances in Clotting Factors: From Bench to Bedside

Molecular approaches for improved clotting factors for hemophilia
Randal J. Kaufman,Jerry S. Powell
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Long-lasting recombinant factor VIII proteins for hemophilia A
Amy D. Shapiro
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders
Margaret V. Ragni
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Evidence-Based Mini-Review
What is the role of prophylaxis in the improvement of health-related quality of life of patients with hemophilia?
David Buchbinder,Margaret V. Ragni
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Allogeneic Transplantation for High-Risk Myelodysplastic Syndromes and AML

Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence
Koen van Besien
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Pharmacological methods to reduce disease recurrence
Charles Craddock
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Older patients/older donors: choosing wisely
Andrew S. Artz
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Aplastic Anemia

Current concepts in the pathophysiology and treatment of aplastic anemia
Neal S. Young
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Allogeneic BM transplantation for the treatment of aplastic anemia: current results and expanding donor possibilities
Gérard Socié
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Management of the refractory aplastic anemia patient: what are the options?
Judith C. W. Marsh,Austin G. Kulasekararaj
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Bad BUGS: Infections Causing Lymphoma

EBV and posttransplantation lymphoproliferative disease: what to do?
Heiner Zimmermann,Ralf U. Trappe
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Human herpesvirus-8: Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma
Lawrence D. Kaplan
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Helicobacter pylori and mucosa-associated lymphoid tissue: what's new
Sung-Hsin Kuo,Ann-Lii Cheng
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Changing Paradigms in Acute Lymphocytic Leukemia: From the Genome to the Patient

Targeting signaling pathways in acute lymphoblastic leukemia: new insights
Christine J. Harrison
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy
Mary V. Relling,Laura B. Ramsey
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors
Anjali S. Advani
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Chronic Lymphocytic Leukemia: A New Treatment Era Is Born

Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies
Michael Hallek
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Immunotherapeutic strategies including transplantation: eradication of disease
John G. Gribben,John C. Riches
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers
Tait Shanafelt
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Chronic Myeloid Leukemia: Refining/Redefining the State of the Art

Which TKI? An embarrassment of riches for chronic myeloid leukemia patients
Timothy Hughes,Deborah White
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Update on current monitoring recommendations in chronic myeloid leukemia: practical points for clinical practice
Vivian G. Oehler
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond
Wesam Ahmed,Richard A. Van Etten
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Evidence-Based Mini-Review
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?
Kendra Sweet,Vivian Oehler
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Clinical Dilemmas in Acute Myeloid Leukemia

High-risk acute myelogenous leukemia: treatment today … and tomorrow
Gary J. Schiller
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?
Peter Paschka,Konstanze Döhner
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
Mark Levis
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Clinical Production and Applications of Natural Killer Cell Immunotherapy

Utilization of mouse models to decipher natural killer cell biology and potential clinical applications
Can M. Sungur,William J. Murphy
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Bringing natural killer cells to the clinic: ex vivo manipulation
Richard W. Childs,Maria Berg
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Therapeutic applications: natural killer cells in the clinic
Jeffrey S. Miller
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Congenital Bleeding Disorders

von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy
David Lillicrap
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
The hemophilias and their clinical management
Neil Josephson
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Inherited platelet disorders including Glanzmann thrombasthenia and Bernard-Soulier syndrome
Reyhan Diz-Küçükkaya
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Disorders of Platelet Destruction

Current management of immune thrombocytopenia
Cindy E. Neunert
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Current consideration and management of disseminated intravascular coagulation
Cheng Hock Toh,Yasir Alhamdi
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies
James T. B. Crawley,Marie A. Scully
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Evidence-Based Mini-Review
Is anti-D immunoglobulin still a frontline treatment option for immune thrombocytopenia?
Jenny M. Despotovic,Cindy E. Neunert
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Finding Treatment for the Untreatable: The Power of Chemical Biology

Drug discovery in academic institutions
Stephen V. Frye
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer
Jonathan G. Drachman,Peter D. Senter
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Opening up drug development to everyone
Burt Adelman
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Genomics in Hematology 101 for the Practicing Clinician

ABCs of genomics
Stefan K. Bohlander
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia
Richard F. Schlenk,Hartmut Döhner
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Genomic stratification for the treatment of lymphomas
Sandeep S. Dave
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Graft Engineering and Adoptive Immunotherapy: Tackling Resistance

Natural killer cells and regulatory T cells: how to manipulate a graft for optimal GVL
Michael R. Verneris
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
T-cell therapy for viral infections
Helen E. Heslop,Ann M. Leen
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
T-cell adoptive immunotherapy for acute lymphoblastic leukemia
Terry J. Fry,Crystal L. Mackall
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Hemoglobinopathies: Fresh Ideas for Management

Genetic association studies in β-hemoglobinopathies
Swee Lay Thein
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies
Deepa Manwani,Paul S. Frenette
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Allogeneic transplantation strategies including haploidentical transplantation in sickle cell disease
Eliane Gluckman
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

HIV in Hematology: What's New?

Pathogenesis and clinical implications of HIV-related anemia in 2013
Amanda J. Redig,Nancy Berliner
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Update on the treatment of HIV-associated hematologic malignancies
Richard F. Little,Kieron Dunleavy
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Transplantation in HIV-infected subjects: is cure possible?
John A. Zaia,Stephen J. Forman
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Hodgkin Lymphoma: New and Old

Novel therapy for Hodgkin lymphoma
Connie Lee Batlevi,Anas Younes
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Management of early-stage Hodgkin lymphoma: is there still a role for radiation?
Peter W. M. Johnson
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment?
Michelle Fanale
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Infectious Disease Complications Encountered by the Practicing Hematologist

Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies
Juan Gea-Banacloche
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Treatment of fungal disease in the setting of neutropenia
Thomas J. Walsh,Maria N. Gamaletsou
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Multidrug-resistant bacteria: what is the threat?
Matteo Bassetti,Elda Righi
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Management of Sickle Cell Disease

Sickle cell disease pain management and the medical home
Jean L. Raphael,Suzette O. Oyeku
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Transfusion therapy for sickle cell disease: a balancing act
Stella T. Chou
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Consequences and management of iron overload in sickle cell disease
John Porter,Maciej Garbowski
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Management of Thromboembolic Disease

The diagnosis and treatment of venous thromboembolism
Philip Wells,David Anderson
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Pros and cons of new oral anticoagulants
Kenneth A. Bauer
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism
Giancarlo Agnelli,Cecilia Becattini
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Multiple Myeloma

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies
Ola Landgren
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
How should we treat newly diagnosed multiple myeloma patients?
María-Victoria Mateos,Jesús F. San Miguel
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients
Philip L. McCarthy,Theresa Hahn
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Myelodysplastic Syndromes: What Makes Therapy Effective?

Prognostic models in myelodysplastic syndromes
Rafael Bejar
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes
Yogen Saunthararajah
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insights
Uwe Platzbecker
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Myeloproliferative Diseases: It's Not ONLY about JAK

JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside
Jason Gotlib
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Focus on the epigenome in the myeloproliferative neoplasms
Eunhee Kim,Omar Abdel-Wahab
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Beyond JAK inhibitor therapy in myelofibrosis
Olatoyosi Odenike
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Non-Hodgkin Lymphomas I: Optimizing Therapy

Targeting B-cell receptor signaling: changing the paradigm
Nathan Fowler,Eric Davis
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Dissecting follicular lymphoma: high versus low risk
Sonali M. Smith
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Transplantation for mantle cell lymphoma: is it the right thing to do?
Michael E. Williams
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Non-Hodgkin Lymphomas II: Breakthroughs in Treatment of High-Grade Lymphomas

Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification
German Ott,Andreas Rosenwald,Elias Campo
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Treatment strategies for aggressive lymphomas: what works?
Wyndham H. Wilson
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP
Leandro Cerchietti,John P. Leonard
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Pediatric Hematology: Insights Applicable to All!

Treatment of infant leukemias: challenge and promise
Patrick Brown
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Hemophagocytic lymphohistiocytosis: pathogenesis and treatment
Gritta E. Janka,Kai Lehmberg
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Novel clinical trials for pediatric leukemias: lessons learned from genomic analyses
Andrea Biondi,Giovanni Cazzaniga
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Evidence-Based Mini-Review
Does hematopoietic stem cell transplantation benefit infants with acute leukemia?
Edward Allan R. Sison,Patrick Brown
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Sports Medicine in Hematology

The use of platelet-rich plasma in the nonsurgical management of sports injuries: hype or hope?
Kimberly G. Harmon,Ashwin L. Rao
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Blood manipulation: current challenges from an anti-doping perspective
Jakob Mørkeberg
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Sickle cell trait testing and athletic participation: a solution in search of a problem?
Alexis A. Thompson
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Transfusion Medicine

Transfusion guidelines: when to transfuse
Zbigniew M. Szczepiorkowski,Nancy M. Dunbar
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Hemochromatosis: the new blood donor
Susan F. Leitman
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Fresh versus old blood: are there differences and do they matter?
James C. Zimring
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Trauma-Induced Coagulopathy: A Clinical and Scientific Perspective

Optimal trauma resuscitation with plasma as the primary resuscitative fluid: the surgeon's perspective
John B. Holcomb,Shibani Pati
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Mechanisms of trauma-induced coagulopathy
Nathan J. White
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Resuscitation of trauma-induced coagulopathy
John R. Hess
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Updates in Aggressive Thrombotic Disease

Heparin-induced thrombocytopenia
Grace M. Lee,Gowthami M. Arepally
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Antiphospholipid syndrome
Wendy Lim
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Cancer-associated thrombosis
Gregory C. Connolly,Charles W. Francis
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Evidence-Based Mini-Review
Should the presence of an antiphospholipid antibody affect the duration of anticoagulant treatment in patients with venous thromboembolism?
David A. Garcia,Wendy Lim
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Errata

Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Hematology Am Soc Hematol Educ Program. 2012;2012:19–27.
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Santini V. Novel therapeutic strategies: hypomethylating agents and beyond. Hematology Am Soc Hematol Educ Program. 2012;2012:65–73.
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2012;2012:88–96.
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
All Issues
Targeted medical therapies for vascular anomalies
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma
Transplant in ALL: who, when, and how?
Ph− ALL: immunotherapy in upfront treatment
Ph+ ALL: new approaches for upfront therapy
  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2025 by American Society of Hematology
 
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal